SrasV1, PascalFrancis, Corpus, bibRecord, 000293

Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses

Identifieur interne : 000293 ( PascalFrancis/Corpus ); précédent : 000292; suivant : 000294

Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses

Auteurs : Matthias Liniger ; Armando Zuniga ; Azaibi Tamin ; Teldja N. Azzouz-Morin ; Marlyse Knuchel ; Rene R. Marty ; Marian Wiegand ; Sara Weibel ; David Kelvin ; Paul A. Rota ; Hussein Y. Naim

Source :

Vaccine [ 0264-410X ] ; 2008.

RBID : Pascal:08-0220446

Descripteurs français

Pascal (Inist)
- Virus syndrome respiratoire aigu sévère, Virus rougeole, Anticorps neutralisant, Immunité humorale, Réponse immune, Immunité cellulaire, Vaccin, Vecteur, Rougeole.

English descriptors

KwdEn :
- Cellular immunity, Humoral immunity, Immune response, Measles, Measles virus, Neutralizing antibody, Severe acute respiratory syndrome virus, Vaccine, Vector.

Abstract

Live attenuated recombinant measles viruses (rMV) expressing a codon-optimised spike glycoprotein (S) or nucleocapsid protein (N) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) were generated (rMV-S and rMV-N). Both recombinant viruses stably expressed the corresponding SARS-CoV proteins, grew to similar end titres as the parental strain and induced high antibody titres against MV and the vectored SARS-CoV antigens (S and N) in transgenic mice susceptible to measles infection. The antibodies induced by rMV-S had a high neutralising effect on SARS-CoV as well as on MV. Moreover, significant N-specific cellular immune responses were measured by IFN-γ ELISPOT assays. The pre-existence of anti-MV antibodies induced by the initial immunisation dose did not inhibit boost of anti-S and anti-N antibodies. Immunisations comprising a mixture of rMV-S and rMV-N induced immune responses similar in magnitude to that of vaccine components administered separately. These data support the suitability of MV as a bivalent candidate vaccine vector against MV and emerging viruses such as SARS-CoV.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0264-410X`
A02	`01`			`@0 VACCDE`
A03		`1`		`@0 Vaccine`
A05				`@2 26`
A06				`@2 17`
A08	`01`	`1`	`ENG`	`@1 Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses`
A11	`01`	`1`		`@1 LINIGER (Matthias)`
A11	`02`	`1`		`@1 ZUNIGA (Armando)`
A11	`03`	`1`		`@1 TAMIN (Azaibi)`
A11	`04`	`1`		`@1 AZZOUZ-MORIN (Teldja N.)`
A11	`05`	`1`		`@1 KNUCHEL (Marlyse)`
A11	`06`	`1`		`@1 MARTY (Rene R.)`
A11	`07`	`1`		`@1 WIEGAND (Marian)`
A11	`08`	`1`		`@1 WEIBEL (Sara)`
A11	`09`	`1`		`@1 KELVIN (David)`
A11	`10`	`1`		`@1 ROTA (Paul A.)`
A11	`11`	`1`		`@1 NAIM (Hussein Y.)`
A14	`01`			`@1 Berna Biotech (a Crucell Company), Rehhagstrasse 79 @2 3018 Bern @3 CHE @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut. @Z 11 aut.`
A14	`02`			`@1 Centers for Disease Control and Prevention, 1600 Clifton Road @2 Atlanta, GA 30333 @3 USA @Z 3 aut. @Z 10 aut.`
A14	`03`			`@1 University Health Network, 610 University Avenue @2 Toronto @3 CAN @Z 9 aut.`
A20				`@1 2164-2174`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20289 @5 354000172681790150`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 50 ref.`
A47	`01`	`1`		`@0 08-0220446`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Vaccine`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Live attenuated recombinant measles viruses (rMV) expressing a codon-optimised spike glycoprotein (S) or nucleocapsid protein (N) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) were generated (rMV-S and rMV-N). Both recombinant viruses stably expressed the corresponding SARS-CoV proteins, grew to similar end titres as the parental strain and induced high antibody titres against MV and the vectored SARS-CoV antigens (S and N) in transgenic mice susceptible to measles infection. The antibodies induced by rMV-S had a high neutralising effect on SARS-CoV as well as on MV. Moreover, significant N-specific cellular immune responses were measured by IFN-γ ELISPOT assays. The pre-existence of anti-MV antibodies induced by the initial immunisation dose did not inhibit boost of anti-S and anti-N antibodies. Immunisations comprising a mixture of rMV-S and rMV-N induced immune responses similar in magnitude to that of vaccine components administered separately. These data support the suitability of MV as a bivalent candidate vaccine vector against MV and emerging viruses such as SARS-CoV.
C02	`01`	`X`		`@0 002A05F04`
C02	`02`	`X`		`@0 002B05C02B`
C02	`03`	`X`		`@0 002A05C10`
C03	`01`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Virus rougeole @2 NW @5 02`
C03	`02`	`X`	`ENG`	`@0 Measles virus @2 NW @5 02`
C03	`02`	`X`	`SPA`	`@0 Measles virus @2 NW @5 02`
C03	`03`	`X`	`FRE`	`@0 Anticorps neutralisant @5 05`
C03	`03`	`X`	`ENG`	`@0 Neutralizing antibody @5 05`
C03	`03`	`X`	`SPA`	`@0 anticuerpo neutralizante @5 05`
C03	`04`	`X`	`FRE`	`@0 Immunité humorale @5 06`
C03	`04`	`X`	`ENG`	`@0 Humoral immunity @5 06`
C03	`04`	`X`	`SPA`	`@0 Inmunidad humoral @5 06`
C03	`05`	`X`	`FRE`	`@0 Réponse immune @5 07`
C03	`05`	`X`	`ENG`	`@0 Immune response @5 07`
C03	`05`	`X`	`SPA`	`@0 Respuesta inmune @5 07`
C03	`06`	`X`	`FRE`	`@0 Immunité cellulaire @5 08`
C03	`06`	`X`	`ENG`	`@0 Cellular immunity @5 08`
C03	`06`	`X`	`SPA`	`@0 Inmunidad celular @5 08`
C03	`07`	`X`	`FRE`	`@0 Vaccin @5 09`
C03	`07`	`X`	`ENG`	`@0 Vaccine @5 09`
C03	`07`	`X`	`SPA`	`@0 Vacuna @5 09`
C03	`08`	`X`	`FRE`	`@0 Vecteur @5 10`
C03	`08`	`X`	`ENG`	`@0 Vector @5 10`
C03	`08`	`X`	`SPA`	`@0 Vector @5 10`
C03	`09`	`X`	`FRE`	`@0 Rougeole @5 14`
C03	`09`	`X`	`ENG`	`@0 Measles @5 14`
C03	`09`	`X`	`SPA`	`@0 Sarampión @5 14`
C07	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Morbillivirus @2 NW`
C07	`05`	`X`	`ENG`	`@0 Morbillivirus @2 NW`
C07	`05`	`X`	`SPA`	`@0 Morbillivirus @2 NW`
C07	`06`	`X`	`FRE`	`@0 Paramyxovirinae @2 NW`
C07	`06`	`X`	`ENG`	`@0 Paramyxovirinae @2 NW`
C07	`06`	`X`	`SPA`	`@0 Paramyxovirinae @2 NW`
C07	`07`	`X`	`FRE`	`@0 Paramyxoviridae @2 NW`
C07	`07`	`X`	`ENG`	`@0 Paramyxoviridae @2 NW`
C07	`07`	`X`	`SPA`	`@0 Paramyxoviridae @2 NW`
C07	`08`	`X`	`FRE`	`@0 Mononegavirales @2 NW`
C07	`08`	`X`	`ENG`	`@0 Mononegavirales @2 NW`
C07	`08`	`X`	`SPA`	`@0 Mononegavirales @2 NW`
C07	`09`	`X`	`FRE`	`@0 Virose`
C07	`09`	`X`	`ENG`	`@0 Viral disease`
C07	`09`	`X`	`SPA`	`@0 Virosis`
C07	`10`	`X`	`FRE`	`@0 Infection`
C07	`10`	`X`	`ENG`	`@0 Infection`
C07	`10`	`X`	`SPA`	`@0 Infección`
N21				`@1 140`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0220446 INIST
ET :	Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses
AU :	LINIGER (Matthias); ZUNIGA (Armando); TAMIN (Azaibi); AZZOUZ-MORIN (Teldja N.); KNUCHEL (Marlyse); MARTY (Rene R.); WIEGAND (Marian); WEIBEL (Sara); KELVIN (David); ROTA (Paul A.); NAIM (Hussein Y.)
AF :	Berna Biotech (a Crucell Company), Rehhagstrasse 79/3018 Bern/Suisse (1 aut., 2 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut., 11 aut.); Centers for Disease Control and Prevention, 1600 Clifton Road/Atlanta, GA 30333/Etats-Unis (3 aut., 10 aut.); University Health Network, 610 University Avenue/Toronto/Canada (9 aut.)
DT :	Publication en série; Niveau analytique
SO :	Vaccine; ISSN 0264-410X; Coden VACCDE; Royaume-Uni; Da. 2008; Vol. 26; No. 17; Pp. 2164-2174; Bibl. 50 ref.
LA :	Anglais
EA :	Live attenuated recombinant measles viruses (rMV) expressing a codon-optimised spike glycoprotein (S) or nucleocapsid protein (N) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) were generated (rMV-S and rMV-N). Both recombinant viruses stably expressed the corresponding SARS-CoV proteins, grew to similar end titres as the parental strain and induced high antibody titres against MV and the vectored SARS-CoV antigens (S and N) in transgenic mice susceptible to measles infection. The antibodies induced by rMV-S had a high neutralising effect on SARS-CoV as well as on MV. Moreover, significant N-specific cellular immune responses were measured by IFN-γ ELISPOT assays. The pre-existence of anti-MV antibodies induced by the initial immunisation dose did not inhibit boost of anti-S and anti-N antibodies. Immunisations comprising a mixture of rMV-S and rMV-N induced immune responses similar in magnitude to that of vaccine components administered separately. These data support the suitability of MV as a bivalent candidate vaccine vector against MV and emerging viruses such as SARS-CoV.
CC :	002A05F04; 002B05C02B; 002A05C10
FD :	Virus syndrome respiratoire aigu sévère; Virus rougeole; Anticorps neutralisant; Immunité humorale; Réponse immune; Immunité cellulaire; Vaccin; Vecteur; Rougeole
FG :	Coronavirus; Coronaviridae; Nidovirales; Virus; Morbillivirus; Paramyxovirinae; Paramyxoviridae; Mononegavirales; Virose; Infection
ED :	Severe acute respiratory syndrome virus; Measles virus; Neutralizing antibody; Humoral immunity; Immune response; Cellular immunity; Vaccine; Vector; Measles
EG :	Coronavirus; Coronaviridae; Nidovirales; Virus; Morbillivirus; Paramyxovirinae; Paramyxoviridae; Mononegavirales; Viral disease; Infection
SD :	Severe acute respiratory syndrome virus; Measles virus; anticuerpo neutralizante; Inmunidad humoral; Respuesta inmune; Inmunidad celular; Vacuna; Vector; Sarampión
LO :	INIST-20289.354000172681790150
ID :	08-0220446

Links to Exploration step

Pascal:08-0220446

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses</title>
<author><name sortKey="Liniger, Matthias" sort="Liniger, Matthias" uniqKey="Liniger M" first="Matthias" last="Liniger">Matthias Liniger</name>
<affiliation><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zuniga, Armando" sort="Zuniga, Armando" uniqKey="Zuniga A" first="Armando" last="Zuniga">Armando Zuniga</name>
<affiliation><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tamin, Azaibi" sort="Tamin, Azaibi" uniqKey="Tamin A" first="Azaibi" last="Tamin">Azaibi Tamin</name>
<affiliation><inist:fA14 i1="02"><s1>Centers for Disease Control and Prevention, 1600 Clifton Road</s1>
<s2>Atlanta, GA 30333</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Azzouz Morin, Teldja N" sort="Azzouz Morin, Teldja N" uniqKey="Azzouz Morin T" first="Teldja N." last="Azzouz-Morin">Teldja N. Azzouz-Morin</name>
<affiliation><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Knuchel, Marlyse" sort="Knuchel, Marlyse" uniqKey="Knuchel M" first="Marlyse" last="Knuchel">Marlyse Knuchel</name>
<affiliation><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marty, Rene R" sort="Marty, Rene R" uniqKey="Marty R" first="Rene R." last="Marty">Rene R. Marty</name>
<affiliation><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wiegand, Marian" sort="Wiegand, Marian" uniqKey="Wiegand M" first="Marian" last="Wiegand">Marian Wiegand</name>
<affiliation><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weibel, Sara" sort="Weibel, Sara" uniqKey="Weibel S" first="Sara" last="Weibel">Sara Weibel</name>
<affiliation><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kelvin, David" sort="Kelvin, David" uniqKey="Kelvin D" first="David" last="Kelvin">David Kelvin</name>
<affiliation><inist:fA14 i1="03"><s1>University Health Network, 610 University Avenue</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rota, Paul A" sort="Rota, Paul A" uniqKey="Rota P" first="Paul A." last="Rota">Paul A. Rota</name>
<affiliation><inist:fA14 i1="02"><s1>Centers for Disease Control and Prevention, 1600 Clifton Road</s1>
<s2>Atlanta, GA 30333</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Naim, Hussein Y" sort="Naim, Hussein Y" uniqKey="Naim H" first="Hussein Y." last="Naim">Hussein Y. Naim</name>
<affiliation><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0220446</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0220446 INIST</idno>
<idno type="RBID">Pascal:08-0220446</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000293</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses</title>
<author><name sortKey="Liniger, Matthias" sort="Liniger, Matthias" uniqKey="Liniger M" first="Matthias" last="Liniger">Matthias Liniger</name>
<affiliation><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zuniga, Armando" sort="Zuniga, Armando" uniqKey="Zuniga A" first="Armando" last="Zuniga">Armando Zuniga</name>
<affiliation><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tamin, Azaibi" sort="Tamin, Azaibi" uniqKey="Tamin A" first="Azaibi" last="Tamin">Azaibi Tamin</name>
<affiliation><inist:fA14 i1="02"><s1>Centers for Disease Control and Prevention, 1600 Clifton Road</s1>
<s2>Atlanta, GA 30333</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Azzouz Morin, Teldja N" sort="Azzouz Morin, Teldja N" uniqKey="Azzouz Morin T" first="Teldja N." last="Azzouz-Morin">Teldja N. Azzouz-Morin</name>
<affiliation><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Knuchel, Marlyse" sort="Knuchel, Marlyse" uniqKey="Knuchel M" first="Marlyse" last="Knuchel">Marlyse Knuchel</name>
<affiliation><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marty, Rene R" sort="Marty, Rene R" uniqKey="Marty R" first="Rene R." last="Marty">Rene R. Marty</name>
<affiliation><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wiegand, Marian" sort="Wiegand, Marian" uniqKey="Wiegand M" first="Marian" last="Wiegand">Marian Wiegand</name>
<affiliation><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weibel, Sara" sort="Weibel, Sara" uniqKey="Weibel S" first="Sara" last="Weibel">Sara Weibel</name>
<affiliation><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kelvin, David" sort="Kelvin, David" uniqKey="Kelvin D" first="David" last="Kelvin">David Kelvin</name>
<affiliation><inist:fA14 i1="03"><s1>University Health Network, 610 University Avenue</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rota, Paul A" sort="Rota, Paul A" uniqKey="Rota P" first="Paul A." last="Rota">Paul A. Rota</name>
<affiliation><inist:fA14 i1="02"><s1>Centers for Disease Control and Prevention, 1600 Clifton Road</s1>
<s2>Atlanta, GA 30333</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Naim, Hussein Y" sort="Naim, Hussein Y" uniqKey="Naim H" first="Hussein Y." last="Naim">Hussein Y. Naim</name>
<affiliation><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cellular immunity</term>
<term>Humoral immunity</term>
<term>Immune response</term>
<term>Measles</term>
<term>Measles virus</term>
<term>Neutralizing antibody</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Vaccine</term>
<term>Vector</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus syndrome respiratoire aigu sévère</term>
<term>Virus rougeole</term>
<term>Anticorps neutralisant</term>
<term>Immunité humorale</term>
<term>Réponse immune</term>
<term>Immunité cellulaire</term>
<term>Vaccin</term>
<term>Vecteur</term>
<term>Rougeole</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Live attenuated recombinant measles viruses (rMV) expressing a codon-optimised spike glycoprotein (S) or nucleocapsid protein (N) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) were generated (rMV-S and rMV-N). Both recombinant viruses stably expressed the corresponding SARS-CoV proteins, grew to similar end titres as the parental strain and induced high antibody titres against MV and the vectored SARS-CoV antigens (S and N) in transgenic mice susceptible to measles infection. The antibodies induced by rMV-S had a high neutralising effect on SARS-CoV as well as on MV. Moreover, significant N-specific cellular immune responses were measured by IFN-γ ELISPOT assays. The pre-existence of anti-MV antibodies induced by the initial immunisation dose did not inhibit boost of anti-S and anti-N antibodies. Immunisations comprising a mixture of rMV-S and rMV-N induced immune responses similar in magnitude to that of vaccine components administered separately. These data support the suitability of MV as a bivalent candidate vaccine vector against MV and emerging viruses such as SARS-CoV.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>17</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LINIGER (Matthias)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ZUNIGA (Armando)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>TAMIN (Azaibi)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>AZZOUZ-MORIN (Teldja N.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>KNUCHEL (Marlyse)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MARTY (Rene R.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>WIEGAND (Marian)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>WEIBEL (Sara)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>KELVIN (David)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>ROTA (Paul A.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>NAIM (Hussein Y.)</s1>
</fA11>
<fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1>
<s2>3018 Bern</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Centers for Disease Control and Prevention, 1600 Clifton Road</s1>
<s2>Atlanta, GA 30333</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>University Health Network, 610 University Avenue</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>2164-2174</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000172681790150</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>50 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0220446</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Live attenuated recombinant measles viruses (rMV) expressing a codon-optimised spike glycoprotein (S) or nucleocapsid protein (N) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) were generated (rMV-S and rMV-N). Both recombinant viruses stably expressed the corresponding SARS-CoV proteins, grew to similar end titres as the parental strain and induced high antibody titres against MV and the vectored SARS-CoV antigens (S and N) in transgenic mice susceptible to measles infection. The antibodies induced by rMV-S had a high neutralising effect on SARS-CoV as well as on MV. Moreover, significant N-specific cellular immune responses were measured by IFN-γ ELISPOT assays. The pre-existence of anti-MV antibodies induced by the initial immunisation dose did not inhibit boost of anti-S and anti-N antibodies. Immunisations comprising a mixture of rMV-S and rMV-N induced immune responses similar in magnitude to that of vaccine components administered separately. These data support the suitability of MV as a bivalent candidate vaccine vector against MV and emerging viruses such as SARS-CoV.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02B</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002A05C10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Virus rougeole</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Measles virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Measles virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Anticorps neutralisant</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Neutralizing antibody</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>anticuerpo neutralizante</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Immunité humorale</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Humoral immunity</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Inmunidad humoral</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Réponse immune</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Immune response</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Respuesta inmune</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Immunité cellulaire</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Cellular immunity</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Inmunidad celular</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Vecteur</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Vector</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Vector</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Rougeole</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Measles</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Sarampión</s0>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Morbillivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Morbillivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Morbillivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Paramyxovirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Paramyxovirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Paramyxovirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Paramyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Paramyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Paramyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Mononegavirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Mononegavirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Mononegavirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fN21><s1>140</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0220446 INIST</NO>
<ET>Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses</ET>
<AU>LINIGER (Matthias); ZUNIGA (Armando); TAMIN (Azaibi); AZZOUZ-MORIN (Teldja N.); KNUCHEL (Marlyse); MARTY (Rene R.); WIEGAND (Marian); WEIBEL (Sara); KELVIN (David); ROTA (Paul A.); NAIM (Hussein Y.)</AU>
<AF>Berna Biotech (a Crucell Company), Rehhagstrasse 79/3018 Bern/Suisse (1 aut., 2 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut., 11 aut.); Centers for Disease Control and Prevention, 1600 Clifton Road/Atlanta, GA 30333/Etats-Unis (3 aut., 10 aut.); University Health Network, 610 University Avenue/Toronto/Canada (9 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Vaccine; ISSN 0264-410X; Coden VACCDE; Royaume-Uni; Da. 2008; Vol. 26; No. 17; Pp. 2164-2174; Bibl. 50 ref.</SO>
<LA>Anglais</LA>
<EA>Live attenuated recombinant measles viruses (rMV) expressing a codon-optimised spike glycoprotein (S) or nucleocapsid protein (N) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) were generated (rMV-S and rMV-N). Both recombinant viruses stably expressed the corresponding SARS-CoV proteins, grew to similar end titres as the parental strain and induced high antibody titres against MV and the vectored SARS-CoV antigens (S and N) in transgenic mice susceptible to measles infection. The antibodies induced by rMV-S had a high neutralising effect on SARS-CoV as well as on MV. Moreover, significant N-specific cellular immune responses were measured by IFN-γ ELISPOT assays. The pre-existence of anti-MV antibodies induced by the initial immunisation dose did not inhibit boost of anti-S and anti-N antibodies. Immunisations comprising a mixture of rMV-S and rMV-N induced immune responses similar in magnitude to that of vaccine components administered separately. These data support the suitability of MV as a bivalent candidate vaccine vector against MV and emerging viruses such as SARS-CoV.</EA>
<CC>002A05F04; 002B05C02B; 002A05C10</CC>
<FD>Virus syndrome respiratoire aigu sévère; Virus rougeole; Anticorps neutralisant; Immunité humorale; Réponse immune; Immunité cellulaire; Vaccin; Vecteur; Rougeole</FD>
<FG>Coronavirus; Coronaviridae; Nidovirales; Virus; Morbillivirus; Paramyxovirinae; Paramyxoviridae; Mononegavirales; Virose; Infection</FG>
<ED>Severe acute respiratory syndrome virus; Measles virus; Neutralizing antibody; Humoral immunity; Immune response; Cellular immunity; Vaccine; Vector; Measles</ED>
<EG>Coronavirus; Coronaviridae; Nidovirales; Virus; Morbillivirus; Paramyxovirinae; Paramyxoviridae; Mononegavirales; Viral disease; Infection</EG>
<SD>Severe acute respiratory syndrome virus; Measles virus; anticuerpo neutralizante; Inmunidad humoral; Respuesta inmune; Inmunidad celular; Vacuna; Vector; Sarampión</SD>
<LO>INIST-20289.354000172681790150</LO>
<ID>08-0220446</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000293 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000293 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0220446
   |texte=   Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses

Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri